BridgeBio Pharma BBIO Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's accounts receivable?
- BridgeBio Pharma (BBIO) reported accounts receivable of $205.23M in Q1 2026.
- How has BridgeBio Pharma's accounts receivable changed year-over-year?
- BridgeBio Pharma's accounts receivable increased by 78.0% year-over-year, from $115.27M to $205.23M.
- What is the long-term trend for BridgeBio Pharma's accounts receivable?
- Over 3 years (2022 to 2025), BridgeBio Pharma's accounts receivable has grown at a 232.5% compound annual growth rate (CAGR), from -$3.79M to $139.44M.
- What does accounts receivable mean?
- The amount of money customers owe the company for products or services already provided.
- How do you interpret accounts receivable?
- A rising balance relative to revenue may indicate collection difficulties, whereas a stable balance suggests efficient credit management.
- How does accounts receivable compare across companies?
- Varies significantly based on the company's commercialization stage and the payment terms of its licensing agreements.